Glioma diagnostics and biomarkers: An ongoing challenge in the field of medicine and science

Expert Review of Molecular Diagnostics

Volumn 14, Issue 4, 2014, Pages 439-452

  Hochberg, Fred H ^a   Atai, Nadia A ^a,b   Gonda, David ^c   Hughes, Michael S ^a   Mawejje, Brolin ^a   Balaj, Leonora ^a   Carter, Robert S ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarker; cancer; CNS; EGFRvIII; exosomes; extracellular vesicles; glioma; isocitrate dehydrogenase 1 2; microvesicles

Indexed keywords

B RAF KINASE; BINDING PROTEIN; BIOLOGICAL MARKER; CHI3L1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FAR UPSTREAM ELEMENT BINDING PROTEIN 1; HISTONE; HISTONE H3F3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATASE; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; TENSIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ALPHA THALASSEMIA MENTAL RETARDATION X LINKED GENE; CANCER SURVIVAL; DNA METHYLATION; DROSOPHILA; DROSOPHILA CAPICUA; EXTRACELLULAR VESICLE; FUSION GENE; GENE; GENE AMPLIFICATION; GENE MUTATION; GLIOMA; HEALTH CARE COST; MEMBRANE VESICLE; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE C MYC; PREVALENCE; REVIEW; TUMOR DIAGNOSIS; AGE DISTRIBUTION; ANIMAL; BRAIN NEOPLASMS; COST OF ILLNESS; GENETICS; HUMAN; METABOLISM; MORTALITY; MUTATION; TRANSPORT VESICLE;

AGE DISTRIBUTION; ANIMALS; BRAIN NEOPLASMS; COST OF ILLNESS; GLIOMA; HUMANS; MUTATION; TRANSPORT VESICLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84898976613     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.905202     Document Type: Review

References (125)

1. Atai NA, Renkema-Mills NA, Bosman J, et al. Differential activity of NADPHproducing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma. J Histochem Cytochem 2011; 59(5):489-503
2. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002;2(8): 569-79 (Pubitemid 37328732
3. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012; 14(Suppl 5):v1-49
4. Grossman SA, Osman M, Hruban R, Piantadosi S. Central nervous system cancers in first-degree relatives and spouses. Cancer Invest 1999;17(5):299-308 (Pubitemid 29266701
5. Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006; 98(21):1528-37 (Pubitemid 44680904
6. Noch E, Khalili K. Oncogenic viruses and tumor glucose metabolism: like kids in a candy store. Mol Cancer Ther 2012;11(1): 14-23
7. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with GBM. Neuro Oncol 2008;10(1):10-18 (Pubitemid 351250896
8. Lehrer S. Cytomegalovirus infection in early childhood may be protective against GBM multiforme, while later infection is a risk factor. Med Hypotheses 2012;78(5):657-8
9. Price RL, Song J, Bingmer K, et al. Cytomegalovirus contributes to GBM in the context of tumor suppressor mutations. Cancer Res 2013;73(11):3441-50
10. Sampson JH, Mitchell DA. Is cytomegalovirus a therapeutic target in GBM? Clin Cancer Res 2011;17(14): 4619-21
11. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of GBM stem-like cells. Nature 2010;468(7325):824-8
12. Wang R, Chadalavada K, Wilshire J, et al. GBM stem-like cells give rise to tumour endothelium. Nature 2010;468(7325): 829-33
13. Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in GBM: a social network. Cancer Res 2011; 71(12):4055-60
14. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. New Engl J Med 2009;360(8):765-73
15. Nickel GC, Barnholtz-Sloan J, Gould MP, et al. Characterizing mutational heterogeneity in a GBM patient with double recurrence. PLoS One 2012;7(4): e35262
16. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of GBM characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17(1):98-110
17. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17(5):510-22
18. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992; 89(7):2965-9
19. Kutikova L, Bowman L, Chang S, et al. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. J Neurooncol 2007;81(1):61-5 (Pubitemid 44963990
20. Chittiboina P, Connor DE Jr, Caldito G, et al. Occult tumors presenting with negative imaging: analysis of the literature. J Neurosurg 2012;116(6):1195-203
21. Available from: www.cdc.gov/nchs/data/hus/2011/123.pdf
22. Khalid L, Carone M, Dumrongpisutikul N, et al. Imaging characteristics of oligodendrogliomas that predict grade. Am J Neuroradiol 2012;33(5):852-7
23. Weber MA, Zoubaa S, Schlieter M, et al. Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Neurology 2006;66(12):1899-906 (Pubitemid 44049824
24. Geer CP, Simonds J, Anvery A, et al. Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study. AJNR Am J Neuroradiol 2012;33(3):556-62
25. Haegler K, Wiesmann M, Bohm C, et al. New similarity search based glioma grading. Neuroradiology 2012;54(8):829-37
26. McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human GBM genes and core pathways. Nature 2008;455(7216):1061-8
27. Stummer W, Van Den Bent MJ, Westphal M. Cytoreductive surgery of GBM as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) 2011; 153(6):1211-18
28. Chang SM, Parney IF, Mcdermott M, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg 2003;98(6): 1175-81 (Pubitemid 36617917
29. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011; 9(Suppl 5):S1-32; quiz S33
30. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncol 2003;5(2): 79-88 (Pubitemid 36422560
31. Stummer W, Kamp MA. The importance of surgical resection in malignant glioma. Curr Opin Neurol 2009;22(6):645-9
32. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with GBM multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004;60(3): 853-60
33. Laperriere NJ, Leung PM, Mckenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998;41(5):1005-11 (Pubitemid 28377480
34. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for GBM. New Engl J Med 2005;352(10):987-96 (Pubitemid 40349501
35. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in GBM in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-66
36. Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neurooncol 2001;3(3):193-200 (Pubitemid 33674111
37. Preusser M, De Ribaupierre S, Wohrer A, et al. Current concepts and management of GBM. Ann Neurol 2011;70(1):9-21
38. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75(1):156-63
39. Sarkaria JN, Kitange GJ, James CD, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 2008;14(10):2900-8
40. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in GBMs during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009;15(14):4622-9
41. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human GBMs is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007;13(7): 2038-45 (Pubitemid 46649870
42. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8(7):1277-80 (Pubitemid 20195640
43. Brem H, Ewend MG, Piantadosi S, et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 1995;26(2):111-23 (Pubitemid 26003222
44. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent GBM multiforme. J Clin Oncol 2007;25(30):4722-9 (Pubitemid 350086473
45. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent GBM. Neurology 2009;73(15):1200-6
46. Fischer I, Cunliffe CH, Bollo RJ, et al. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol 2008;10(5): 700-8
47. Rock JP, Hearshen D, Scarpace L, et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002;51(4): 912-19; discussion 919-920
48. Chen WW, Balaj L, Liau LM, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids 2013;2: e109
49. Hole P, Sillence K, Hannell C, et al. Interlaboratory comparison of size measurements on nanoparticles using nanoparticle tracking analysis (NTA). J Nanopart Res 2013;15:2101
50. Skog J, Wurdinger T, Van Rijn S, et al. GBM microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10(12):1470-6
51. Schageman J, Zeringer E, Li M, et al. The complete exosome workflow solution: from isolation to characterization of RNA cargo. Biomed Res Int 2013;2013:253957
52. Balaj L, Lessard R, Dai L, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun 2011;2:180
53. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in GBM multiforme patients. Clin Cancer Res 2005;11(4): 1462-6 (Pubitemid 40315227
54. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of GBM. J Clin Oncol 2007;25(16):2288-94 (Pubitemid 46954657
55. Camara-Quintana JQ, Nitta RT, Li G. Pathology: commonly monitored GBM markers: EFGR, EGFRvIII, PTEN, and MGMT. Neurosurg Clin N Am 2012; 23(2):237-46; vIII
56. Weller M, Kaulich K, Hentschel B, et al. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer 2013 Oct 31
57. Li G, Mitra SS, Monje M, et al. Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. J Neurooncol 2012;108(3): 395-402
58. Bruzzone MG, Eoli M, Cuccarini V, et al. Genetic signature of adult gliomas and correlation with MRI features. Expert Rev Mol Diagn 2009;9(7):709-20
59. Ciesielski MJ, Kazim AL, Barth RF, Fenstermaker RA. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 2005;54(2):107-19 (Pubitemid 40100833
60. Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005;11(21):7841-50 (Pubitemid 41611629
61. Van Den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent GBM: EORTC brain tumor group study 26034. J Clin Oncol 2009;27(8):1268-74
62. Brown PD, Krishnan S, Sarkaria JN, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed GBMmultiforme: north Central Cancer Treatment Group Study N0177. J Clin Oncol 2008;26(34):5603-9
63. Tanaka S, Louis DN, Curry WT, et al. Diagnostic and therapeutic avenues for GBM: no longer a dead end? Nat Rev Clin Oncol 2013;10(1):14-26
64. Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 2012;38(3):271-91
65. Chen WW, Balaj L, Liau LM, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acid 2013;2: e109
66. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed GBM: a prospective translational study of the German Glioma Network. J Clin Oncol 2009;27(34):5743-50
67. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 2013;3(7):730-41
68. Jones PS, Dunn GP, Barker FG II, et al. Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th Annual Frye-Halloran Brain Tumor Symposium. Neurosurg Focus 2013;34(2):E9
69. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009;118(4): 469-74
70. Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012;226(1):7-16
71. Sahm F, Koelsche C, Meyer J, et al. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 2012; 123(6):853-60
72. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012;3(7): 709-22
73. Lee CJ, Chan WI, Scotting PJ. CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas. J Neurooncol 2005; 73(2):101-8 (Pubitemid 40974029
74. Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333(6048):1453-5
75. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric GBM. Nature 2012;482(7384):226-31
76. Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012;124(5):615-25
77. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013;110(15): 6021-6
78. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121(3):397-405
79. Schiffman JD, Hodgson JG, Vandenberg SR, et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010; 70(2):512-19
80. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16
81. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366(8):707-14
82. Chen P, Zou P, Yan Q, et al. The TERT MNS16A polymorphism contributes to cancer susceptibility: meta-analysis of the current studies. Gene 2013;519(2):266-70
83. Wu G, Broniscer A, Mceachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem GBMs. Nat Genet 2012; 44(3):251-3
84. Xing WJ, Zou Y, Han QL, et al. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG GBM cell proliferation induced by protein kinase inhibitors. Clin Exp Pharmacol Physiol 2013;40(1):13-21
85. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359(4):366-77
86. Jeuken JW, Wesseling P. MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential. J Pathol 2010;222(4): 324-8
87. Forshew T, Tatevossian RG, Lawson AR, et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009;218(2):172-81
88. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008;68(21):8673-7
89. Tihan T, Ersen A, Qaddoumi I, et al. Pathologic characteristics of pediatric intracranial pilocytic astrocytomas and their impact on outcome in 3 countries: a multi-institutional study. Am J Surg Pathol 2012;36(1):43-55
90. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in GBM. N Engl J Med 2005;352(10):997-1003 (Pubitemid 40349502
91. Dunn J, Baborie A, Alam F, et al. Extent of MGMT promoter methylation correlates with outcome in GBMs given temozolomide and radiotherapy. Br J Cancer 2009;101(1):124-31
92. Balana C, Carrato C, Ramirez JL, et al. Tumour and serum MGMT promoter methylation and protein expression in GBM patients. Clin Transl Oncol 2011;13(9): 677-85
93. Weaver KD, Grossman SA, Herman JG. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest 2006;24(1):35-40 (Pubitemid 43247271
94. Pelloski CE, Mahajan A, Maor M, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in GBM. Clin Cancer Res 2005; 11(9):3326-34 (Pubitemid 40627883
95. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002;62(15):4364-8 (Pubitemid 34827294
96. Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012 Aug 2;488(7409):49-56
97. Baldewpersad Tewarie NM, Burgers IA, Dawood Y, et al. NADP+ -dependent IDH1 R132 mutation and its relevance for glioma patient survival. Med Hypotheses 2013;80(6):728-31
98. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001; 8(2):83-96 (Pubitemid 32641351
99. Choi BD, Archer GE, Mitchell DA, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009;19(4): 713-23
100. Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIIIpositive GBM. Core Evid 2012;7:93-103
101. Perry J, Okamoto M, Guiou M, et al. Novel therapies in GBM. Neurol Res Int 2012;2012:428565
102. Fu Y, Huang R, Du J, et al. Glioma-derived mutations in IDH: from mechanism to potential therapy. Biochem Biophys Res Commun 2010;397(2):127-30
103. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340(6132): 626-30
104. Wang F, Travins J, Delabarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013;340(6132): 622-6
105. You Y, Geng X, Zhao P, et al. Evaluation of combination gene therapy with PTEN and antisense hTERT for malignant glioma in vitro and xenografts. Cell Mol Life Sci 2007;64(5):621-31 (Pubitemid 46712464
106. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6(2):117-27 (Pubitemid 39485684
107. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011;6(3):e17948
108. Flaherty KT. Narrative review: BRAF opens the door for therapeutic advances in melanoma. Ann Intern Med 2010;153(9): 587-91
109. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363(9):809-19
110. Joseph EW, Pratilas CA, Poulikakos PI, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010;107(33):14903-8
111. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008;105(8): 3041-6 (Pubitemid 351723664
112. De Roock W, De Vriendt V, Normanno N, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12(6):594-603
113. Bobustuc GC, Baker CH, Limaye A, et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes GBM cells to temozolomide. Neuro-oncol 2010;12(9): 917-27
114. Di Vinci A, Casciano I, Marasco E, et al. Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome. J Cancer Res Clin Oncol 2012;138(1):35-47
115. Roth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L)-telomerase-based cancer therapy. Recent Results Cancer Res 2010;184:221-34
116. Chen W, Xiao BK, Liu JP, et al. Alternative lengthening of telomeres in hTERT-inhibited laryngeal cancer cells. Cancer Sci 2010;101(8):1769-76
117. CSR, Incorporated. Evaluation of Patient Recruitment Strategies Phase I Feasibility Study. Final Report 2006
118. Marks RG, Conlon M, Ruberg SJ. Paradigm shifts in clinical trials enabled by information technology. Stat Med 2001; 20(17-18):2683-96 (Pubitemid 32834376
119. Tan DS, Thomas GV, Garrett MD, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009;15(5):406-20
120. Diehl F, Li M, He Y, et al. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 2006; 3(7):551-9 (Pubitemid 43941774
121. Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009;27(9):858-63
122. Li M, Diehl F, Dressman D, et al. BEAMing up for detection and quantification of rare sequence variants. Nat Methods 2006;3(2):95-7 (Pubitemid 43173307
123. Atai NA, Balaj L, Van Veen H, et al. Heparin blocks transfer of ectracellular vesicles between donor and recipient cells. J Neurooncol 2013;115(3):343-51
124. Shao H, Chung J, Balaj L, et al. Protein typing of circulating microvesicles allows real-time monitoring of GBM therapy. Nat Med 2012;18(12):1835-40
125. Boisselier B, Gallego Perez-Larraya J, Rossetto M, et al. Detection of IDH1 mutation in the plasma of patients with glioma. Neurology 2012;79(16): 1693-8